ZILA Zila (MM)

Pursuant to Zila Inc.'s (Nasdaq GM: ZILA) Employee Stock Purchase Plan, and a Rule 10b5-1 Plan, which was announced December 13, 2005, Douglas D. Burkett, Ph.D., Chairman, Chief Executive Officer and President of Zila purchased 6,527 shares of Zila common stock on July 19, 2006. The purchase reflects shares with a purchase price equal to 10% of Dr. Burkett's salary for the first half of calendar 2006. About Zila Zila, Inc., headquartered in Phoenix, is an innovator in preventive healthcare technologies and products, focusing on enhanced body defense and the detection of pre-disease states. Zila has three business units: -- Zila Biotechnology, a research, development and licensing business specializing in pre-cancer/cancer detection through its patented Zila Tolonium Chloride and OraTest(R) technologies. -- Zila Pharmaceuticals, a manufacturer and marketer of products to promote oral health and prevent oral disease, including ViziLite(R) Plus oral examination kits and Peridex(R) prescription periodontal rinse. -- Zila Nutraceuticals, manufacturer and marketer of Ester-C(R) and Ester-E(R), branded, highly effective forms of Advanced Protection vitamins C and E. For more information about Zila, visit www.zila.com.